Key Perspectives: Cilta-Cel in Multiple Myeloma
Panelists discuss how long-term CARTITUDE-1 data may change clinical practice by validating earlier use of ciltacabtagene autoleucel (cilta-cel) and informing personalized treatment strategies based on risk and disease biology.
Long-term follow-up from CARTITUDE-1 is prompting a shift in clinical practice, including earlier consideration of chimeric antigen receptor T-cell therapy. The trial has influenced regulatory agencies to accept minimal residual disease as a surrogate for survival in new studies.
As new therapies like bispecifics and trispecific antibodies emerge, clinicians must tailor treatment sequencing. Yet, cilta-cel remains a cornerstone therapy, especially for younger, fit patients or those with high-risk features who may benefit most from its curative potential.
Ultimately, these findings challenge the long-standing notion that multiple myeloma is incurable, offering new hope and optimism to patients and clinicians alike.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
